Why the study?
Do NOACs reduce thromboembolic events and bleeding compared to VKAs in patients with CKD and atrial fibrillation or venous thromboembolism?
Population
10,616 patients with CKD and atrial fibrillation or venous thromboembolism, pooled from 8 randomized…
Comparison
Novel oral anticoagulants for at least 4 weeks'… vs Vitamin K antagonists (VKAs).
Design
Meta-analysis
Follow-up
at least 4 weeks
Authors
Loading...
Comparable efficacy and safety support NOAC or VKA selection in moderate CKD; extends evidence to this subgroup.
Do NOACs reduce thromboembolic events and bleeding compared to VKAs in patients with CKD and atrial fibrillation or venous thromboembolism?
NOACs demonstrate similar efficacy and safety compared to VKAs in patients with moderate CKD (creatinine clearance 30-50 ml/min) requiring anticoagulation for atrial fibrillation or venous thromboembolism.
Harel et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: